- Type of paper
: Paper in journal
Title: High doses of epirubicin and 5-fluorouracile in the
treatment of advenced gastric cancer
- Authors:
- Roth, Anton (41573)
- Kolarić, Krsto (21661)
Journal: Annals of Oncology, suppl. 1
Number: 1
Volume: 3
Year: 1992
Pages: from 154 to 154
Language: engleski
Keywords: epirubicin, 5-fluorouracile, gastric cancer
- Type of paper
: Paper in journal
Title: High doses of epirubicin and 5-fluorouracile in the
treatment of advanced gastric cancer - phase II study
- Authors:
- Roth, Anton (41573)
- Kolarić, Krsto (21661)
- Županc, Darko (119423)
- Roth, Andrej
- Luetić, Josip
Journal: Libri Oncol.
Number: 3
Volume: 21
Year: 1992
Pages: from 173 to 177
Number of references: 25
Language: engleski
Summary: From March 1988 to March 1991 51 patients with metastatic
gastric cancer (Phase II Study) were administered combination therapy
including high doses of epirubicin aand 5-fluorouracil. Out of 51 patients
who entered the study 43 were evaluable (> 2 cycles of chemotherapy). The
range of the patients' age was 33-70 years (M=55,6 years). In twenty-seven
patients the performance score was <2, and in sixten 3 (WHO). Twenty-three
patients underwent surgery 5-38 months prior to chemotherapy. The disease
was primary inoperable in 20 patients. Distant metastases were recorded in
the lymph nodes (21), liver (15), peritoneum (11), pleura (5), lungs (4),
skin (2), bones (2) and brain (1). The disease was measurable in 28 and
evauable but not measurable in 15 patients. Combined treatment involved 120
mg/m2i.v. of epirubicin on day 1, and 1000 mg/m2 of 5-fluorouracil in
6-hour infusion on days 1, 2, 3, 4, 5. The cycles were repeated after 4
weeks. Seventeen partial and 2 complete remissions were achieved (44%
response rate; confidence interval 30-60%). The average survival of the
responders was 9 months, and that of non-responders 5 monaths. Toxicity was
moderate, reversible and well tolerated. The presented data confirm the
esablished antitumorigenic activity and tolerabilty of high doses of
5-fluorouracil in the treatment of metastatic gastric cancer.
Keywords: gastric cancer, epirubicin, 5-fluorouracil
- Type of paper
: Paper in journal
Title: High doses epirubicin and 5-fluorouracil with or without
cisplatin in advanced gastric cancer - a preliminary report of a randomized
study
- Authors:
- Roth, Anton (41573)
- Kolarić, Krsto (21661)
- Županc, Darko (119423)
Journal: Libri Oncol.
Number: 3
Volume: 23
Year: 1994
Pages: from 187 to 193
Number of references: 34
Language: engleski
Summary: From semteber 1991 to August 1994 75 patients with advaced
gastric cancer entered phase III clinical trial. The aim of study was to
determine activity of high doses of 5-fluorouracil and epirubicin (FE) vs.
the same combination+cisplatin (FEP) in that group of patients. Out of 75
patients 62 (44 males and 18 females) were evaluable (>2 cycles of
chemotherapy) The range of patient's age was 27-70 years (M=56), and ECOG
performance status was < 3. The treatment involved in FE arm 120 mg/m2 of
epirubicin i.v. on day 1, and 1000 mg/m2 in 6-hour infusion of
5-fluorouracil on days 1,2,3,4,5; in FEP arm the same combination +
cisplatin 30 mg/m2 on days 2,4 was administered. The cycles were repeated
after 4 weeks. In FE arm, 33 patients were evaluable with 10 partial and 1
complete remission (33,3%,and in FEP arm out of 29 evaluable patients 11
partial and 1 complete remission (41,4%) were observed. Median survival in
FE group was 6,2 mos, and in FEP group 8,2 mos. Test results so far did not
reveal the statistically significant difference between the two treatmens
applied. Toxicity was tolerable and reversible. Our trial being still under
way, the final results wil provide a more accurate answer with regard to
the value of the two administered protocols.
Keywords: gastric cancer, epirubicin, 5-fluorouracil, cisplatin
- Type of paper
: Paper in journal
Title: Does the addition of cisplatin to high doses of
5-fluorouracil and epirubicin in advanced gastric cancer results in better
responne to therapy
- Authors:
- Roth, Anton (41573)
- Kolarić, Krsto (21661)
- Županc, Darko (119423)
Journal: Annals of Oncology, suppl. 1
Volume: 7
Year: 1996
Pages: from 136 to 136
Language: engleski
Keywords: cisplatin, advanced gastric cancer
- Type of paper
: Summary in proceedings
Title: Chemotherapy of gastric cancer: randomised clinical study
(Phase III) FE vs, FEP-preliminary report
- Authors:
- Roth, Anton (41573)
- Kolarić, Krsto (21661)
- Županc, Darko (119423)
Proceedings title: Abstract book
Language: engleski
Place: New Delhi, Indija
Year: 1994
Meeting: XVI International cancer congres
Held: from 10/30/94 to 11/05/94
Keywords: metastatic gastric cancer, cisplatin, epirubicin, 5-fluorouracil
- Type of paper
: Summary in proceedings
Title: High doses of epirubicin and 5-fluorouracile with or
without cisplatin in advanced gastric cancer - preliminary report
- Authors:
- Roth, Anton (41573)
- Kolarić, Krsto (21661)
- Županc, Darko (119423)
Proceedings title: Abstract book
Language: engleski
Place: Oslo, Norveška
Year: 1994
Pages: from 188 to 188
Meeting: 3rd United European Gastroenterology week
Held: from 06/25/94 to 06/29/94
Keywords: chemotherapy, gastric cancer
- Type of paper
: Summary in proceedings
Title: Chemotherapy of gastric cancer FE:FEP (randomsed study)
- Authors:
- Roth, Anton (41573)
- Kolarić, Krsto (21661)
- Županc, Darko (119423)
Proceedings title: 4th United European Gastroenterology week
Language: engleski
Place: Berlin, Njemačka
Year: 1995
Pages: from 213 to 213
Meeting: 4th United European Gastroenterology week
Held: from 09/13/95 to 09/17/95
Keywords: chemotherapy, gastric cancer
- Type of paper
: Summary in proceedings
Title: High doses of epirubicin and 5-fluorouracile with or
without cisplatin in advanced gastric cancer
- Authors:
- Roth, Anton (41573)
- Kolarić, Krsto (21661)
- Županc, Darko (119423)
Proceedings title: Abstract book
Language: engleski
Place: Paris, Francuska
Year: 1995
Pages: from 117 to 117
Meeting: ECCO 8th European Cancer Conference
Held: from 10/29/95 to 11/02/95
Keywords: cisplatin, gastric cancer
